{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:54:55Z","timestamp":1792896895696,"version":"4.5.0"},"reference-count":393,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020896","name":"United Arab Emirates University Zayed Bin Sultan Center for Health Sciences","doi-asserted-by":"publisher","award":["31R140"],"award-info":[{"award-number":["31R140"]}],"id":[{"id":"10.13039\/501100020896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020896","name":"United Arab Emirates University Zayed Bin Sultan Center for Health Sciences","doi-asserted-by":"publisher","award":["21M187"],"award-info":[{"award-number":["21M187"]}],"id":[{"id":"10.13039\/501100020896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006014","name":"United Arab Emirates University College of Medicine and Health Sciences","doi-asserted-by":"publisher","award":["NP-24-09"],"award-info":[{"award-number":["NP-24-09"]}],"id":[{"id":"10.13039\/501100006014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007866","name":"College of Medicine and Health Sciences, University of Gondar","doi-asserted-by":"publisher","award":["VRI\\u201020\\u201010"],"award-info":[{"award-number":["VRI\\u201020\\u201010"]}],"id":[{"id":"10.13039\/501100007866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["12M215"],"award-info":[{"award-number":["12M215"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["12M103"],"award-info":[{"award-number":["12M103"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["12M136"],"award-info":[{"award-number":["12M136"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006013","name":"United Arab Emirates University","doi-asserted-by":"publisher","award":["12M218"],"award-info":[{"award-number":["12M218"]}],"id":[{"id":"10.13039\/501100006013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100024160","name":"ASPIRE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024160","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jmb.2025.169473","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:13:48Z","timestamp":1759536828000},"page":"169473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects"],"prefix":"10.1016","volume":"437","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6269-9759","authenticated-orcid":false,"given":"Soumeya Ali","family":"Jaballah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6423-9123","authenticated-orcid":false,"given":"Lizna M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-640X","authenticated-orcid":false,"given":"Mohammad Abdullah","family":"Jehad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0880-2396","authenticated-orcid":false,"given":"Shaima","family":"Akhlaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-1678","authenticated-orcid":false,"given":"Tahir A.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-3756","authenticated-orcid":false,"given":"Farah","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2025.169473_b0005","series-title":"Experiments in Plant-Hybridisation","author":"Mendel","year":"1925"},{"key":"10.1016\/j.jmb.2025.169473_b0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ng0501-92","article-title":"Gene therapy restores vision in a canine model of childhood blindness","volume":"28","author":"Acland","year":"2001","journal-title":"Nature Genet."},{"key":"10.1016\/j.jmb.2025.169473_b0015","first-page":"37","article-title":"Limiting science: a biologist\u2019s perspective","volume":"107","author":"Baltimore","year":"1978","journal-title":"Daedalus"},{"key":"10.1016\/j.jmb.2025.169473_b0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0030","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0035","unstructured":"Cindy Kisik, adult with ADA-SCID, advocates for mental health awareness, Immune Deficiency Foundation, 2022. https:\/\/primaryimmune.org\/resources\/news-articles\/cindy-kisik-adult-ada-scid-advocates-mental-health-awareness (accessed September 9, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0040","unstructured":"Final evaluation determination \u2013 Strimvelis for treating adenosine deaminase deficiency\u2013severe combined immunodeficiency, 2017. https:\/\/www.nice.org.uk\/guidance\/hst7\/documents\/final-evaluation-determination-document (accessed August 18, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0045","unstructured":"ZYNTEGLO, FDA, 2022. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zynteglo (accessed September 10, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0050","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0055","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nature.2017.22694","article-title":"Chinese scientists fix genetic disorder in cloned human embryos","volume":"550","author":"Cyranoski","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/331035a0","article-title":"Lineage-specific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells","volume":"331","author":"Dzierzak","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0065","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.175.4025.949","article-title":"Gene therapy for human genetic disease?","volume":"175","author":"Friedmann","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.58.1.240","article-title":"The enzymatic repair of DNA. I. Formation of circular lambda-DNA","volume":"58","author":"Gefter","year":"1967","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1073\/pnas.57.1.148","article-title":"Formation of covalent circles of lambda DNA by E. coli extracts","volume":"57","author":"Gellert","year":"1967","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0080","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4049\/jimmunol.149.2.438","article-title":"Functional expression of human CD8 in fully reconstituted mice after retroviral-mediated gene transfer of hemopoietic stem cells","volume":"149","author":"Holl\u00e4nder","year":"1992","journal-title":"J. Immunol. (Baltim. Md. 1950)"},{"key":"10.1016\/j.jmb.2025.169473_b0095","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1365-2958.2002.02839.x","article-title":"Identification of genes that are associated with DNA repeats in prokaryotes","volume":"43","author":"Jansen","year":"2002","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.jmb.2025.169473_b0100","unstructured":"Kymriah, Novartis Pharmaceuticals Corporation, KYMRIAH, US Food Drug Adm. 2017. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah (accessed August 18, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0105","article-title":"Long term survival following DeltaRex-G\/DeltaVax tumor-targeted gene therapy for advanced chemotherapy-resistant malignancies: an academic milestone","volume":"6","author":"Liu","year":"2021","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169473_b0110","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-CT133","article-title":"Abstract CT133: A phase I trial of PD-1 deficient engineered T cells with CRISPR\/Cas9 in patients with advanced non-small cell lung cancer with PD-L1 expression","volume":"78","author":"Lu","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jmb.2025.169473_b0115","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1182\/blood.V80.2.396.396","article-title":"Stem cell factor, interleukin-3, and interleukin-6 promote retroviral-mediated gene transfer into murine hematopoietic stem cells","volume":"80","author":"Luskey","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b0120","unstructured":"Lyfgenia, bluebird bio, Inc., LYFGENIA, US Food Drug Adm., 2023. https:\/\/www.fda.gov\/vaccines-blood-biologics\/lyfgenia."},{"key":"10.1016\/j.jmb.2025.169473_b0125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via Cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0130","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.bbrc.2005.07.089","article-title":"Design, engineering, and characterization of zinc finger nucleases","volume":"335","author":"Mani","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jmb.2025.169473_b0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0092-8674(76)90001-5","article-title":"Amplification and characterization of a beta-globin gene synthesized in vitro","volume":"8","author":"Maniatis","year":"1976","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169473_b0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0092-8674(83)90344-6","article-title":"Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus","volume":"33","author":"Mann","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169473_b0145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bmj.326.7382.181\/a","article-title":"FDA halts gene therapy trials after leukaemia case in France","volume":"326","author":"Marwick","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jmb.2025.169473_b0150","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0155","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0160","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1073\/pnas.57.5.1426","article-title":"Linkage of polynucleotides through phosphodiester bonds by an enzyme from Escherichia coli","volume":"57","author":"Olivera","year":"1967","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nbt0104-3","article-title":"China approves first gene therapy","volume":"22","author":"Pearson","year":"2004","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b0170","unstructured":"Pho-Conners, V. Four Obstacles in Cell and Gene Therapy Development, Mission Bio, 2021. https:\/\/missionbio.com\/company\/blog\/four-obstacles-cell-and-gene-therapy\/ (accessed April 7, 2024)."},{"key":"10.1016\/j.jmb.2025.169473_b0175","unstructured":"U.S. Food and Drug Administration, ABECMA (idecabtagene vicleucel), (2024). https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel (accessed June 20, 2024)."},{"key":"10.1016\/j.jmb.2025.169473_b0180","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/219749a0","article-title":"Use of viruses as carriers of added genetic information","volume":"219","author":"Rogers","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0185","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans \u2014 immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0190","first-page":"1612","article-title":"Death but one unintended consequence of gene-therapy trial","volume":"164","author":"Sibbald","year":"2001","journal-title":"CMAJ Can. Med. Assoc. J."},{"key":"10.1016\/j.jmb.2025.169473_b0195","unstructured":"U.S. Food and Drug Administration, SKYSONA. 2022. https:\/\/www.fda.gov\/vaccines-blood-biologics\/skysona (accessed August 18, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0200","unstructured":"Smithies, O. (1982) Notebook entry: 1982 (\u03b3). Dr. Oliver Smithies Research Archive https:\/\/smithies.lib.unc.edu\/notebooks\/1981-1990\/1982-%ce%b3\/ (accessed September 15, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0205","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1101\/SQB.1984.049.01.019","article-title":"Homologous recombination with DNA introduced into mammalian cells Cold Spring Harb","volume":"49","author":"Smithies","year":"1984","journal-title":"Symp. Quant. Biol."},{"key":"10.1016\/j.jmb.2025.169473_b0210","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1128\/JVI.00182-10","article-title":"Self-inactivating alpharetroviral vectors with a split-packaging design","volume":"84","author":"Suerth","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0215","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nature03556","article-title":"Highly efficient endogenous human gene correction using designed zinc-finger nucleases","volume":"435","author":"Urnov","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0220","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1073\/pnas.57.4.1021","article-title":"Enzymatic breakage and joining of deoxyribonucleic acid, I. Repair of single-strand breaks in DNA by an enzyme system from Escherichia coli infected with T4 bacteriophage","volume":"57","author":"Weiss","year":"1967","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0225","unstructured":"U.S. Food and Drug Administration (2017) YESCARTA (axicabtagene ciloleucel). https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta (accessed July 1, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0230","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/genetics\/41.5.758","article-title":"Transductional heterogenotes in Escherichia coli","volume":"41","author":"Morse","year":"1956","journal-title":"Genetics"},{"key":"10.1016\/j.jmb.2025.169473_b0235","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/jb.64.5.679-699.1952","article-title":"Genetic exchange in Salmonella","volume":"64","author":"Zinder","year":"1952","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.jmb.2025.169473_b0240","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1073\/pnas.58.5.1996","article-title":"The enzymatic repair of DNA, II. Characterization of phage-induced sealase","volume":"58","author":"Becker","year":"1967","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0245","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/0006-291X(67)90353-1","article-title":"Polynucleotide cellulose as a substrate for a polynucleotide ligase induced by phage T4","volume":"28","author":"Cozzarelli","year":"1967","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jmb.2025.169473_b0250","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1073\/pnas.61.1.237","article-title":"Enzymatic joining of polynucleotides, V. A DNA-adenylate intermediate in the polynucleotide-joining reaction","volume":"61","author":"Olivera","year":"1968","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0255","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/2171110a0","article-title":"DNA restriction enzyme from E. coli","volume":"217","author":"Meselson","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0260","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0022-2836(70)90149-X","article-title":"A restriction enzyme from Hemophilus influenzae","volume":"51","author":"Smith","year":"1970","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2025.169473_b0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/hum.1990.1.3-331","article-title":"The ADA human gene therapy clinical protocol: points to consider response with clinical protocol, July 6, 1990","volume":"1","author":"Anderson","year":"1990","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0270","unstructured":"S. Fields, M. Johnston, When the Gene Is the Cure: Immunodeficiency and Gene Therapy, in: Genet. Twists Fate Internet, MIT Press, 2010. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559901\/ (accessed July 7, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0275","unstructured":"S.W. Brusilow, A.L. Horwich, Urea Cycle Enzymes, in: D.L. Valle, S. Antonarakis, A. Ballabio, A.L. Beaudet, G.A. Mitchell (Eds.), Online Metab. Mol. Bases Inherit. Dis., McGraw-Hill Education, New York, NY, 1995. ommbid.mhmedical.com\/content.aspx?aid=1181435469 (accessed July 15, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1090-3798(03)00040-0","article-title":"Ornithine transcarbamylase deficiency: a urea cycle defect","volume":"7","author":"Gordon","year":"2003","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc."},{"key":"10.1016\/j.jmb.2025.169473_b0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jgg.2015.04.003","article-title":"Genotype-phenotype correlations in ornithine transcarbamylase deficiency: a mutation update","volume":"42","author":"Caldovic","year":"2015","journal-title":"J. Genet. Genom. Yi Chuan Xue Bao"},{"key":"10.1016\/j.jmb.2025.169473_b0290","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymgme.2008.12.016","article-title":"Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency","volume":"96","author":"Wilson","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jmb.2025.169473_b0295","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41577-022-00800-6","article-title":"Gene therapy for inborn errors of immunity: past, present and future","volume":"23","author":"Fischer","year":"2023","journal-title":"Nature Rev. Immunol."},{"key":"10.1016\/j.jmb.2025.169473_b0300","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/hum.2015.137","article-title":"Gene therapy for X-linked severe combined immunodeficiency: where do we stand?","volume":"27","author":"Cavazzana","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0305","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169473_b0310","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jmb.2025.169473_b0315","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0320","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(04)17590-9","article-title":"Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector","volume":"364","author":"Gaspar","year":"2004","journal-title":"Lancet London Engl."},{"key":"10.1016\/j.jmb.2025.169473_b0325","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0330","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jmb.2025.169473_b0335","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/hum.1992.3.5-479","article-title":"A model for predicting the risk of cancer consequent to retroviral gene therapy","volume":"3","author":"Moolten","year":"1992","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0340","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/08977199309011023","article-title":"Distinct classes of factor-independent mutants can be isolated after retroviral mutagenesis of a human myeloid stem cell line","volume":"8","author":"Stocking","year":"1993","journal-title":"Growth Factors Chur Switz."},{"key":"10.1016\/j.jmb.2025.169473_b0345","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/nbt1216","article-title":"Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration","volume":"24","author":"Montini","year":"2006","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b0350","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.mt.6300393","article-title":"Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency","volume":"16","author":"Thornhill","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0355","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/mt.2008.5","article-title":"Physiological promoters reduce the genotoxic risk of integrating gene vectors","volume":"16","author":"Zychlinski","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0360","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0365","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jmb.2025.169473_b0370","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1134\/S0006297922080090","article-title":"CRISPR-Cas9: a history of its discovery and ethical considerations of its use in genome editing","volume":"87","author":"Gostimskaya","year":"2022","journal-title":"Biochem. Biokhimiia"},{"key":"10.1016\/j.jmb.2025.169473_b0375","unstructured":"American Society of Gene & Cell Therapy, ASGCT Quarterly Gene, Cell, and RNA Therapy Landscape Report, 2025. https:\/\/www.asgct.org\/publications\/landscape-report\/2025 (accessed September 13, 2025)."},{"key":"10.1016\/j.jmb.2025.169473_b0380","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","article-title":"Entering the modern era of gene therapy","volume":"70","author":"Anguela","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0385","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jmb.2025.169473_b0390","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0395","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1182\/blood.V124.21.550.550","article-title":"Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma","volume":"124","author":"Kochenderfer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b0400","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude Shannon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0405","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jmb.2025.169473_b0410","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1200\/jco.2015.33.15_suppl.8515","article-title":"Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel\/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)","volume":"33","author":"Sauter","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jmb.2025.169473_b0415","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0420","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jmb.2025.169473_b0425","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jmb.2025.169473_b0430","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0435","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0440","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b0445","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/WNL.0b013e3181c29356","article-title":"Safety and tolerability of putaminal AADC gene therapy for Parkinson disease","volume":"73","author":"Christine","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jmb.2025.169473_b0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0455","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0460","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0465","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/mt.2010.135","article-title":"A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson\u2019s disease","volume":"18","author":"Muramatsu","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0470","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0475","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fgene.2019.00868","article-title":"Development and clinical translation of approved gene therapy products for genetic disorders","volume":"10","author":"Shahryari","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.jmb.2025.169473_b0480","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/s41591-021-01467-7","article-title":"Record number of gene-therapy trials, despite setbacks","volume":"27","author":"Arnold","year":"2021","journal-title":"Nature Med."},{"key":"10.1016\/j.jmb.2025.169473_b0485","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1479-0556-2-9","article-title":"The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery","volume":"2","author":"Anson","year":"2004","journal-title":"Genet. Vaccines Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0490","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/s41434-021-00237-x","article-title":"Retroviral gene therapy in Germany with a view on previous experience and future perspectives","volume":"28","author":"Morgan","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0495","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the potential of viral and nonviral vectors in gene therapy: a review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.jmb.2025.169473_b0500","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/v15030698","article-title":"Viral vectors in gene therapy: where do we stand in 2023?","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b0505","first-page":"313","article-title":"Pressing diseases that represent promising targets for gene therapy","volume":"24","author":"Beitelshees","year":"2017","journal-title":"Discov. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0510","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.jmb.2025.169473_b0515","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10258","article-title":"Viral vector\u2010based gene therapies in the clinic","volume":"7","author":"Zhao","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0520","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0525","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nature Nanotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b0530","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nature Rev. Genet."},{"key":"10.1016\/j.jmb.2025.169473_b0535","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jmb.2025.169473_b0540","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nature Rev. Genet."},{"key":"10.1016\/j.jmb.2025.169473_b0545","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/pcmedi\/pbab014","article-title":"Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics","volume":"4","author":"Liu","year":"2021","journal-title":"Precis. Clin. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0550","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1038\/s41467-020-17552-3","article-title":"Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins","volume":"11","author":"Pavani","year":"2020","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169473_b0555","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","article-title":"CRISPR gene therapy: applications, limitations, and implications for the future","volume":"10","author":"Uddin","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jmb.2025.169473_b0560","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jmb.2025.169473_b0565","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/jpet.122.001234","article-title":"RNAi-based therapeutics and novel RNA bioengineering technologies","volume":"384","author":"Traber","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-019-0748-z","article-title":"Noncoding RNAs in cancer therapy resistance and targeted drug development","volume":"12","author":"Wang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jmb.2025.169473_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0580","series-title":"Retroviruses","article-title":"Development and Applications of Retroviral Vectors","author":"Miller","year":"1997"},{"key":"10.1016\/j.jmb.2025.169473_b0585","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/365666a0","article-title":"A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells","volume":"365","author":"Bukrinsky","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0590","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.3390\/v3112192","article-title":"The molecular biology of feline immunodeficiency virus (FIV)","volume":"3","author":"Kenyon","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b0595","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.272.5259.263","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0600","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nm0398-354","article-title":"Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors","volume":"4","author":"Poeschla","year":"1998","journal-title":"Nature Med."},{"key":"10.1016\/j.jmb.2025.169473_b0605","first-page":"1","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2013.06.003","article-title":"Understanding and altering cell tropism of vesicular stomatitis virus","volume":"176","author":"Hastie","year":"2013","journal-title":"Virus Res."},{"key":"10.1016\/j.jmb.2025.169473_b0615","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","article-title":"Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy","volume":"2","author":"Vigna","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jmb.2025.169473_b0620","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/2261209a0","article-title":"RNA-dependent DNA polymerase in virions of RNA tumour viruses","volume":"226","author":"Baltimore","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0625","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/2261211a0","article-title":"RNA-dependent DNA polymerase in virions of Rous sarcoma virus","volume":"226","author":"Temin","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167924","article-title":"Understanding retroviral life cycle and its genomic RNA packaging","volume":"435","author":"Chameettachal","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2025.169473_b0635","doi-asserted-by":"crossref","first-page":"8087","DOI":"10.1128\/jvi.71.11.8087-8095.1997","article-title":"Primer tRNAs for reverse transcription","volume":"71","author":"Mak","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0640","series-title":"Retroviruses","year":"1997"},{"key":"10.1016\/j.jmb.2025.169473_b0645","series-title":"Retroviruses","article-title":"Retroviral Virions and Genomes","author":"Vogt","year":"1997"},{"key":"10.1016\/j.jmb.2025.169473_b0650","series-title":"Retroviruses","article-title":"Viral Entry and Receptors","author":"Hunter","year":"1997"},{"key":"10.1016\/j.jmb.2025.169473_b0655","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nrmicro1599","article-title":"Translational control of retroviruses","volume":"5","author":"Balvay","year":"2007","journal-title":"Nature Rev. Microbiol."},{"key":"10.1016\/j.jmb.2025.169473_b0660","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2174\/1570162052772924","article-title":"HIV-1 TAR RNA: the target of molecular interactions between the virus and its host","volume":"3","author":"Bannwarth","year":"2005","journal-title":"Curr. HIV Res."},{"key":"10.1016\/j.jmb.2025.169473_b0665","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1742-4690-2-69","article-title":"Tat gets the \u201cgreen\u201d light on transcription initiation","volume":"2","author":"Brady","year":"2005","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmb.2025.169473_b0670","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/ilar\/ilv044","article-title":"Lessons learned from mouse mammary tumor virus in animal models","volume":"57","author":"Dudley","year":"2016","journal-title":"ILAR J."},{"key":"10.1016\/j.jmb.2025.169473_b0675","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0092-8674(89)90279-1","article-title":"HIV TAR: an RNA enhancer?","volume":"59","author":"Sharp","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169473_b0680","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1128\/jvi.66.8.4814-4823.1992","article-title":"Transcriptional interaction between retroviral long terminal repeats (LTRs): mechanism of 5\u2032 LTR suppression and 3\u2032 LTR promoter activation of c-myc in avian B-cell lymphomas","volume":"66","author":"Boerkoel","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0685","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1128\/jvi.68.6.3830-3840.1994","article-title":"Comparison of 5\u2032 and 3\u2032 long terminal repeat promoter function in human immunodeficiency virus","volume":"68","author":"Klaver","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0690","series-title":"Encycl. Cancer","first-page":"3293","article-title":"Retroviral Insertional Mutagenesis","author":"Slape","year":"2011"},{"key":"10.1016\/j.jmb.2025.169473_b0695","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1128\/jvi.71.9.6534-6540.1997","article-title":"Genetic determinant of rapid-onset B-cell lymphoma by avian leukosis virus","volume":"71","author":"Smith","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0700","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12977-023-00619-6","article-title":"Biomolecular condensates: insights into early and late steps of the HIV-1 replication cycle","volume":"20","author":"Di Nunzio","year":"2023","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmb.2025.169473_b0705","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-4690-1-9","article-title":"Early steps of retrovirus replicative cycle","volume":"1","author":"Nisole","year":"2004","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmb.2025.169473_b0710","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-virology-031413-085502","article-title":"Live cell imaging of retroviral entry","volume":"1","author":"Hulme","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0715","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1073\/pnas.1920631117","article-title":"HIV-1 uncoats in the nucleus near sites of integration","volume":"117","author":"Burdick","year":"2020","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0720","article-title":"HIV-1 cores retain their integrity until minutes before uncoating in the nucleus","volume":"118","author":"Li","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0725","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-virology-020922-110929","article-title":"Nuclear capsid uncoating and reverse transcription of HIV-1","volume":"9","author":"M\u00fcller","year":"2022","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0730","doi-asserted-by":"crossref","first-page":"12730","DOI":"10.1021\/acs.chemrev.6b00125","article-title":"Retroviral DNA integration","volume":"116","author":"Lesbats","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jmb.2025.169473_b0735","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coviro.2016.02.008","article-title":"Retrovirus maturation-an extraordinary structural transformation","volume":"18","author":"Mattei","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0740","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0042-6822(84)90250-2","article-title":"Mutagenesis of the region between env and src of the SR-A strain of Rous sarcoma virus for the purpose of constructing helper-independent vectors","volume":"136","author":"Hughes","year":"1984","journal-title":"Virology"},{"key":"10.1016\/j.jmb.2025.169473_b0745","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1089\/aid.1997.13.1077","article-title":"Use of a green fluorescent protein as a marker for human immunodeficiency virus type 1 infection","volume":"13","author":"Page","year":"1997","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.jmb.2025.169473_b0750","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1073\/pnas.82.4.1141","article-title":"Replication-competent Moloney murine leukemia virus carrying a bacterial suppressor tRNA gene: selective cloning of proviral and flanking host sequences","volume":"82","author":"Reik","year":"1985","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0755","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1128\/jvi.66.5.2731-2739.1992","article-title":"Human immunodeficiency virus vectors for inducible expression of foreign genes","volume":"66","author":"Buchschacher","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0760","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1126\/science.8235655","article-title":"Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes","volume":"262","author":"Delwart","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0765","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00204747","article-title":"Development of retroviral vectors as safe, targeted gene delivery systems","volume":"74","author":"G\u00fcnzburg","year":"1996","journal-title":"J. Mol. Med. Berl. Ger."},{"key":"10.1016\/j.jmb.2025.169473_b0770","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/v12101106","article-title":"Gene Therapy applications of non-human lentiviral vectors","volume":"12","author":"Munis","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b0775","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0684.1992.tb00570.x","article-title":"Simian immunodeficiency virus vectors: replication and pseudotyping","volume":"21","author":"Rizvi","year":"1992","journal-title":"J. Med. Primatol."},{"key":"10.1016\/j.jmb.2025.169473_b0780","first-page":"17","article-title":"Retroviral vectors for cancer gene therapy, recent results cancer res. Fortschritte Krebsforsch","volume":"209","author":"Schambach","year":"2016","journal-title":"Progres Dans Rech. Sur Cancer"},{"key":"10.1016\/j.jmb.2025.169473_b0785","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/bies.201500051","article-title":"Retroviral integration: site matters","volume":"37","author":"Demeulemeester","year":"2015","journal-title":"Bioessays"},{"key":"10.1016\/j.jmb.2025.169473_b0790","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1371\/journal.pbio.0020234","article-title":"Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences","volume":"2","author":"Mitchell","year":"2004","journal-title":"PLoS Biol."},{"key":"10.1016\/j.jmb.2025.169473_b0795","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.1083413","article-title":"Transcription start regions in the human genome are favored targets for MLV integration","volume":"300","author":"Wu","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b0800","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1038\/mtna.2014.33","article-title":"BET-independent MLV-based vectors target away from promoters and regulatory elements","volume":"3","author":"El Ashkar","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jmb.2025.169473_b0805","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.omtn.2017.04.002","article-title":"Engineering next-generation BET-independent MLV vectors for safer gene therapy","volume":"7","author":"El Ashkar","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jmb.2025.169473_b0810","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/v10030116","article-title":"Proviruses with long-term stable expression accumulate in transcriptionally active chromatin close to the gene regulatory elements: comparison OF ASLV- HIV- and MLV-derived vectors","volume":"10","author":"Mikl\u00edk","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b0815","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/v15010032","article-title":"Determinants of retroviral integration and implications for gene therapeutic MLV\u2014based vectors and for a cure for HIV-1 infection","volume":"15","author":"Pellaers","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b0820","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1084\/jem.174.6.1477","article-title":"Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes","volume":"174","author":"Weinberg","year":"1991","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jmb.2025.169473_b0825","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/nm1329","article-title":"A role for LEDGF\/p75 in targeting HIV DNA integration","volume":"11","author":"Ciuffi","year":"2005","journal-title":"Nature Med."},{"key":"10.1016\/j.jmb.2025.169473_b0830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/nar\/gkl885","article-title":"LEDGF\/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro","volume":"35","author":"Cherepanov","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169473_b0835","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00007-22","article-title":"Single-cell imaging shows that the transcriptional state of the HIV-1 provirus and its reactivation potential depend on the integration site","volume":"13","author":"Janssens","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.jmb.2025.169473_b0840","doi-asserted-by":"crossref","first-page":"8820","DOI":"10.1128\/JVI.00719-06","article-title":"Integration site choice of a feline immunodeficiency virus vector","volume":"80","author":"Kang","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0845","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1038\/mtna.2012.60","article-title":"Intrapulmonary versus nasal transduction of murine airways with GP64-pseudotyped viral vectors","volume":"2","author":"Oakland","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jmb.2025.169473_b0850","doi-asserted-by":"crossref","first-page":"15175","DOI":"10.1128\/JVI.79.24.15175-15188.2005","article-title":"Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5\u03b1 proteins","volume":"79","author":"Saenz","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0855","doi-asserted-by":"crossref","first-page":"12199","DOI":"10.1128\/JVI.79.19.12199-12204.2005","article-title":"Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1","volume":"79","author":"Crise","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0860","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-4690-4-2","article-title":"SIVSM\/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells","volume":"4","author":"Goujon","year":"2007","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmb.2025.169473_b0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000057","article-title":"Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction","volume":"4","author":"Sharova","year":"2008","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jmb.2025.169473_b0870","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1089\/104303401750148847","article-title":"Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system","volume":"12","author":"Pandya","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0875","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/jvi.67.5.2681-2688.1993","article-title":"Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles","volume":"67","author":"Rizvi","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0880","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1128\/JVI.73.4.2832-2840.1999","article-title":"Lentivirus vectors using human and simian immunodeficiency virus elements","volume":"73","author":"White","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0885","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00418-017-1569-1","article-title":"Tropism, intracerebral distribution, and transduction efficiency of HIV- and SIV-based lentiviral vectors after injection into the mouse brain: a qualitative and quantitative in vivo study","volume":"148","author":"Hlavat\u00fd","year":"2017","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169473_b0890","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/s41467-022-29928-8","article-title":"Multivalent interactions essential for lentiviral integrase function","volume":"13","author":"Ballandras-Colas","year":"2022","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169473_b0895","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ymthe.2006.06.006","article-title":"The integration profile of EIAV-based vectors","volume":"14","author":"Hacker","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0900","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.3390\/v7062769","article-title":"Characterization of equine infectious anemia virus integration in the horse genome","volume":"7","author":"Liu","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b0905","article-title":"Characterization of equine infectious anemia virus long terminal repeat quasispecies in vitro and in vivo","volume":"92","author":"Wang","year":"2018","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.jmb.2025.169473_b0910","doi-asserted-by":"crossref","first-page":"163","DOI":"10.24425\/pjvs.2023.145019","article-title":"Review and future perspectives on the integration characteristics for equine lentivirus in the host genome","volume":"26","author":"Yu","year":"2023","journal-title":"Pol. J. Vet. Sci."},{"key":"10.1016\/j.jmb.2025.169473_b0915","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/gt.2009.20","article-title":"Development of inducible EIAV-based lentiviral vector packaging and producer cell lines","volume":"16","author":"Stewart","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0920","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/sj.gt.3300768","article-title":"Gene transfer vectors derived from equine infectious anemia virus","volume":"5","author":"Olsen","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0925","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(13)61939-X","article-title":"Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson\u2019s disease: a dose escalation, open-label, phase 1\/2 trial","volume":"383","author":"Palfi","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jmb.2025.169473_b0930","doi-asserted-by":"crossref","first-page":"12035","DOI":"10.1128\/JVI.79.18.12035-12044.2005","article-title":"Integration targeting by avian sarcoma-leukosis virus and human immunodeficiency virus in the chicken genome","volume":"79","author":"Barr","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0935","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/jvi.40.2.421-430.1981","article-title":"Integration of Rous sarcoma virus DNA into chicken embryo fibroblasts: no preferred proviral acceptor site in the DNA of clones of singly infected transformed chicken cells","volume":"40","author":"Lerner","year":"1981","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0940","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3390\/genes5020415","article-title":"Genome-wide analysis of alpharetroviral integration in human hematopoietic stem\/progenitor cells","volume":"5","author":"Moiani","year":"2014","journal-title":"Genes"},{"key":"10.1016\/j.jmb.2025.169473_b0945","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1742-4690-11-34","article-title":"Mouse mammary tumor virus-based vector transduces non-dividing cells, enters the nucleus via a TNPO3-independent pathway and integrates in a less biased fashion than other retroviruses","volume":"11","author":"Konstantoulas","year":"2014","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmb.2025.169473_b0950","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1128\/JVI.02098-07","article-title":"Mouse mammary tumor virus integration site selection in human and mouse genomes","volume":"82","author":"Faschinger","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0955","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004250","article-title":"Chromatin landscapes of retroviral and transposon integration profiles","volume":"10","author":"de Jong","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.jmb.2025.169473_b0960","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00015-21","article-title":"Oncolytic foamy virus: generation and properties of a nonpathogenic replicating retroviral vector system that targets chronically proliferating cancer cells","volume":"95","author":"Budzik","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0965","doi-asserted-by":"crossref","first-page":"36610","DOI":"10.1038\/srep36610","article-title":"Retargeted foamy virus vectors integrate less frequently near proto-oncogenes","volume":"6","author":"Hocum","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169473_b0970","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1073\/pnas.0510046103","article-title":"Foamy virus vector integration sites in normal human cells","volume":"103","author":"Trobridge","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b0975","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01639-17","article-title":"Foamy virus vector carries a strong insulator in its long terminal repeat which reduces its genotoxic potential","volume":"92","author":"Goodman","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0980","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/s41417-022-00431-y","article-title":"Evaluation of the stability and intratumoral delivery of foreign transgenes encoded by an oncolytic Foamy Virus vector","volume":"29","author":"Budzik","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0985","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2005.16.741","article-title":"Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses","volume":"16","author":"Abordo-Adesida","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b0990","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1128\/JVI.01899-09","article-title":"The Requirement for Cellular Transportin 3 (TNPO3 or TRN-SR2) during infection maps to human immunodeficiency virus type 1 capsid and not integrase","volume":"84","author":"Krishnan","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b0995","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002194","article-title":"Transportin 3 promotes a nuclear maturation step required for efficient HIV-1 integration","volume":"7","author":"Zhou","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jmb.2025.169473_b1000","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaut.2017.07.005","article-title":"Twenty-five years of gene therapy for genetic diseases and leukemia: the road to marketing authorization of the first ex vivo gene therapies","volume":"85","author":"Bordignon","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jmb.2025.169473_b1005","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/emboj\/20.7.1726","article-title":"The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation","volume":"20","author":"Jordan","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.jmb.2025.169473_b1010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","article-title":"HIV-1 integration in the human genome favors active genes and local hotspots","volume":"110","author":"Schr\u00f6der","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169473_b1015","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1093\/nar\/gkaa536","article-title":"The chromatin landscape at the HIV-1 provirus integration site determines viral expression","volume":"48","author":"Vansant","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169473_b1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2022.198813","article-title":"Identification of novel integration sites for bovine leukemia virus proviral DNA in cancer driver genes in cattle with persistent lymphocytosis","volume":"317","author":"Babii","year":"2022","journal-title":"Virus Res."},{"key":"10.1016\/j.jmb.2025.169473_b1025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/jvi.49.2.615-620.1984","article-title":"Nucleotide sequence analysis of the long terminal repeat of integrated bovine leukemia provirus DNA and of adjacent viral and host sequences","volume":"49","author":"Couez","year":"1984","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1030","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1128\/JVI.02752-06","article-title":"Human T-cell leukemia virus type 1 integration target sites in the human genome: comparison with those of other retroviruses","volume":"81","author":"Derse","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1035","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1073\/pnas.77.5.2577","article-title":"Genomic integration of bovine leukemia provirus: comparison of persistent lymphocytosis with lymph node tumor form of enzootic","volume":"77","author":"Kettmann","year":"1980","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b1040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/jvi.47.1.146-150.1983","article-title":"Chromosome integration domain for bovine leukemia provirus in tumors","volume":"47","author":"Kettmann","year":"1983","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004006","article-title":"Clonality of HTLV-2 in natural infection","volume":"10","author":"Melamed","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jmb.2025.169473_b1050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.virusres.2011.01.004","article-title":"Bovine leukemia virus integration site selection in cattle that develop leukemia","volume":"156","author":"Murakami","year":"2011","journal-title":"Virus Res."},{"key":"10.1016\/j.jmb.2025.169473_b1055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00109-015-1327-6","article-title":"Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors","volume":"94","author":"Suerth","year":"2016","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jmb.2025.169473_b1060","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1089\/10430349950016942","article-title":"Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy","volume":"10","author":"Loeb","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1065","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1128\/JVI.73.4.2886-2892.1999","article-title":"Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors","volume":"73","author":"Zufferey","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1070","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/sj.gt.3301221","article-title":"Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain","volume":"7","author":"Paterna","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1075","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1038\/sj.emboj.7601740","article-title":"HIV\u20101 DNA Flap formation promotes uncoating of the pre\u2010integration complex at the nuclear pore","volume":"26","author":"Arhel","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.jmb.2025.169473_b1080","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/88115","article-title":"The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain","volume":"19","author":"Zennou","year":"2001","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1085","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1073\/pnas.79.19.5986","article-title":"Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5\u2032 long terminal repeat and the start of the gag gene","volume":"79","author":"Watanabe","year":"1982","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b1090","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1073\/pnas.83.10.3194","article-title":"Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells","volume":"83","author":"Yu","year":"1986","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b1095","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.mt.6300152","article-title":"Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors","volume":"15","author":"Schambach","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1100","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/sj.gt.3301892","article-title":"Construction of a retroviral vector production system with the minimum possibility of a homologous recombination","volume":"10","author":"Yu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1105","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/nar\/23.4.628","article-title":"A transient three-plasmid expression system for the production of high titer retroviral vectors","volume":"23","author":"Soneoka","year":"1995","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169473_b1110","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/v8100276","article-title":"Cross- and co-packaging of retroviral RNAs and their consequences","volume":"8","author":"Ali","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b1115","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b1120","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/sj.gt.3302807","article-title":"Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors","volume":"13","author":"Schambach","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1006\/viro.1999.9850","article-title":"Self-inactivating lentiviral vectors with U3 and U5 modifications","volume":"261","author":"Iwakuma","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.jmb.2025.169473_b1130","doi-asserted-by":"crossref","first-page":"9873","DOI":"10.1128\/JVI.72.12.9873-9880.1998","article-title":"Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery","volume":"72","author":"Zufferey","year":"1998","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.jmb.2025.169473_b1135","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jmb.2025.169473_b1140","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/JVI.74.5.2365-2371.2000","article-title":"Split-intron retroviral vectors: enhanced expression with improved safety","volume":"74","author":"Ismail","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/toxsci\/kfw220","article-title":"Viral vectors: the road to reducing genotoxicity","volume":"155","author":"David","year":"2017","journal-title":"Toxicol. Sci. off. J. Soc. Toxicol."},{"key":"10.1016\/j.jmb.2025.169473_b1150","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/hum.2010.233","article-title":"The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors","volume":"22","author":"Emery","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1155","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1073\/pnas.160159597","article-title":"A chromatin insulator protects retrovirus vectors from chromosomal position effects","volume":"97","author":"Emery","year":"2000","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b1160","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/mt.2009.7","article-title":"Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator","volume":"17","author":"Li","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1165","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2007-04-085506","article-title":"An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation","volume":"111","author":"Ryu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b1170","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b1175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jmb.2025.169473_b1180","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1185","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMoa2027675","article-title":"Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency","volume":"384","author":"Kohn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b1190","doi-asserted-by":"crossref","first-page":"8421","DOI":"10.1128\/JVI.78.16.8421-8436.2004","article-title":"Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration","volume":"78","author":"Logan","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1195","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1128\/JVI.79.14.9359-9362.2005","article-title":"Reduced mobilization of Rev-responsive element-deficient lentiviral vectors","volume":"79","author":"Lucke","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/mthe.2000.0095","article-title":"Development of a novel trans-lentiviral vector that affords predictable safety","volume":"2","author":"Wu","year":"2000","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1205","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12929-022-00865-4","article-title":"Delivering genes with human immunodeficiency virus-derived vehicles: still state-of-the-art after 25 years","volume":"29","author":"Wolff","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jmb.2025.169473_b1215","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1182\/blood-2010-05-283523","article-title":"High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors","volume":"116","author":"Cattoglio","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b1220","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1128\/JVI.00011-14","article-title":"Enhancers are major targets for murine leukemia virus vector integration","volume":"88","author":"De Ravin","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0020423","article-title":"Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells","volume":"2","author":"Hematti","year":"2004","journal-title":"PLoS Biol."},{"key":"10.1016\/j.jmb.2025.169473_b1230","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature14226","article-title":"Nuclear architecture dictates HIV-1 integration site selection","volume":"521","author":"Marini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b1235","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/mt.2009.16","article-title":"Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells","volume":"17","author":"Wang","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.omtm.2017.10.001","article-title":"Interactions between retroviruses and the host cell genome","volume":"8","author":"Poletti","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"Pt 3","key":"10.1016\/j.jmb.2025.169473_b1245","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1099\/0022-1317-76-3-691","article-title":"Helper virus-free transfer of human immunodeficiency virus type 1 vectors","volume":"76","author":"Richardson","year":"1995","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1250","doi-asserted-by":"crossref","first-page":"5129","DOI":"10.1128\/JVI.75.11.5129-5140.2001","article-title":"Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions","volume":"75","author":"Browning","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/338254a0","article-title":"The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA","volume":"338","author":"Malim","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b1260","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0092-8674(00)80939-3","article-title":"A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA","volume":"92","author":"Wei","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169473_b1265","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.coche.2018.09.007","article-title":"Progressing from transient to stable packaging cell lines for continuous production of lentiviral and gammaretroviral vectors","volume":"22","author":"Park","year":"2018","journal-title":"Curr. Opin. Chem. Eng."},{"key":"10.1016\/j.jmb.2025.169473_b1270","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1042\/BJ20120146","article-title":"Lentiviral vectors: basic to translational","volume":"443","author":"Sakuma","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.jmb.2025.169473_b1275","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1128\/jvi.74.10.4839-4852.2000","article-title":"A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene","volume":"74","author":"Kotsopoulou","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1280","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1089\/hgtb.2013.015","article-title":"Analysis of partial recombinants in lentiviral vector preparations","volume":"25","author":"Kuate","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.jmb.2025.169473_b1285","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt.3062","article-title":"Genomic discovery of potent chromatin insulators for human gene therapy","volume":"33","author":"Liu","year":"2015","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1472-6750-9-13","article-title":"Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants","volume":"9","author":"Nielsen","year":"2009","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1295","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jviromet.2006.04.003","article-title":"Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes","volume":"136","author":"Osti","year":"2006","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jmb.2025.169473_b1300","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/sj.mt.6300259","article-title":"Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element","volume":"15","author":"Arumugam","year":"2007","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1305","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrg1925","article-title":"Insulators: exploiting transcriptional and epigenetic mechanisms","volume":"7","author":"Gaszner","year":"2006","journal-title":"Nature Rev. Genet."},{"key":"10.1016\/j.jmb.2025.169473_b1310","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","article-title":"Gene therapy in patients with transfusion-dependent \u03b2-thalassemia","volume":"378","author":"Thompson","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jmb.2025.169473_b1315","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1182\/blood-2001-11-0042","article-title":"Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates","volume":"100","author":"Sandrin","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b1320","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/v17060802","article-title":"Progress in pseudotyping lentiviral vectors towards cell-specific gene delivery in vivo","volume":"17","author":"Arduini","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b1325","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b1330","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.1128\/jvi.69.12.7430-7436.1995","article-title":"High-titer packaging cells producing recombinant retroviruses resistant to human serum","volume":"69","author":"Cosset","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1335","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.gt.3302189","article-title":"Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells","volume":"11","author":"Strang","year":"2004","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1340","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jgm.691","article-title":"RD114-pseudotyped retroviral vectors kill cancer cells by syncytium formation and enhance the cytotoxic effect of the TK\/GCV gene therapy strategy","volume":"7","author":"Germain","year":"2005","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jmb.2025.169473_b1345","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/hum.2009.001","article-title":"Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media","volume":"20","author":"Ghani","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1350","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1006\/mthe.2002.0549","article-title":"Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood","volume":"5","author":"Hanawa","year":"2002","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1355","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtm.2022.12.006","article-title":"Efficient clinical-grade \u03b3-retroviral vector purification by high-speed centrifugation for CAR T cell manufacturing","volume":"28","author":"Mekkaoui","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1360","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1006\/mthe.2002.0690","article-title":"Five recombinant simian immunodeficiency virus pseudotypes lead to exclusive transduction of retinal pigmented epithelium in rat","volume":"6","author":"Duisit","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1365","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1006\/mthe.2002.0681","article-title":"Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes","volume":"6","author":"MacKenzie","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1370","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.virol.2010.06.004","article-title":"Effects of retroviral envelope-protein cleavage upon trafficking, incorporation, and membrane fusion","volume":"405","author":"Apte","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.jmb.2025.169473_b1375","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.top59","article-title":"Engineering the surface glycoproteins of lentiviral vectors for targeted gene transfer","volume":"2009","author":"Verhoeyen","year":"2009","journal-title":"Cold Spring Harb Protoc"},{"key":"10.1016\/j.jmb.2025.169473_b1380","doi-asserted-by":"crossref","first-page":"339","DOI":"10.14348\/molcells.2017.0043","article-title":"Stability of retroviral vectors against ultracentrifugation is determined by the viral internal core and envelope proteins used for pseudotyping","volume":"40","author":"Kim","year":"2017","journal-title":"Mol. Cells"},{"key":"10.1016\/j.jmb.2025.169473_b1385","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jgm.2837","article-title":"Regulated expression of murine CD40L by a lentiviral vector transcriptionally targeted through its endogenous promoter","volume":"17","author":"Fern\u00e1ndez-Rubio","year":"2015","journal-title":"J. Gene Med."},{"key":"10.1016\/j.jmb.2025.169473_b1390","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2002-02-0578","article-title":"Specific transgene expression in human and mouse CD4+cells using lentiviral vectors with regulatory sequences from theCD4 gene","volume":"101","author":"Marodon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b1395","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1128\/JVI.72.5.4212-4223.1998","article-title":"Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers","volume":"72","author":"Jooss","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1400","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3390\/cells13231963","article-title":"Synthetic promoters in gene therapy: design approaches, features and applications","volume":"13","author":"Artemyev","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.jmb.2025.169473_b1405","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1006\/mthe.2002.0588","article-title":"Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity","volume":"5","author":"Glover","year":"2002","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1410","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1525-0016(02)00060-6","article-title":"In vitro and in vivo comparative study of chimeric liver-specific promoters","volume":"7","author":"Kramer","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1415","series-title":"Adv. Cancer Res.","first-page":"253","article-title":"Chapter Eight \u2013 Applications of tissue-specific and cancer-selective gene promoters for cancer diagnosis and therapy","author":"Kumar","year":"2023"},{"key":"10.1016\/j.jmb.2025.169473_b1420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6750-10-58","article-title":"Novel strong tissue specific promoter for gene expression in human germ cells","volume":"10","author":"Kuzmin","year":"2010","journal-title":"BMC Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1425","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605380","article-title":"Strategies for targeting gene therapy in cancer cells with tumor-specific promoters","volume":"10","author":"Monta\u00f1o-Samaniego","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jmb.2025.169473_b1430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13205-025-04366-7","article-title":"Advances in viral vector-based delivery systems for gene therapy: a comprehensive review","volume":"15","author":"Singh","year":"2025","journal-title":"3 Biotech"},{"key":"10.1016\/j.jmb.2025.169473_b1435","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/gt.2008.104","article-title":"Construction and analysis of compact muscle-specific promoters for AAV vectors","volume":"15","author":"Wang","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1440","series-title":"Gene Ther. Protoc.","first-page":"205","article-title":"Evaluation of Promoters for Use in Tissue-Specific Gene Delivery","author":"Zheng","year":"2008"},{"key":"10.1016\/j.jmb.2025.169473_b1445","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nm1398","article-title":"Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer","volume":"12","author":"Brown","year":"2006","journal-title":"Nature Med."},{"key":"10.1016\/j.jmb.2025.169473_b1450","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1006\/mthe.2002.0542","article-title":"Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors","volume":"5","author":"Vigna","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1455","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1093\/nar\/16.12.5263","article-title":"Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus","volume":"16","author":"Ham","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169473_b1460","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3109\/08830185.2014.917412","article-title":"Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses","volume":"33","author":"Chicaybam","year":"2014","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.jmb.2025.169473_b1465","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/s12951-025-03512-w","article-title":"Advancing liver cancer treatment with dual-targeting CAR-T therapy","volume":"23","author":"Yang","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1470","doi-asserted-by":"crossref","DOI":"10.1155\/jimr\/5845167","article-title":"Advancements and future directions of dual-target chimeric antigen receptor T-cell therapy in preclinical and clinical studies","volume":"2025","author":"Zhang","year":"2025","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jmb.2025.169473_b1475","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/13543776.2016.1211640","article-title":"Cancer suicide gene therapy: a patent review","volume":"26","author":"Navarro","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jmb.2025.169473_b1480","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","article-title":"Progress and problems with the use of suicide genes for targeted cancer therapy","volume":"99","author":"Karjoo","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jmb.2025.169473_b1485","article-title":"Synthetic promoters enhance gene therapy precision","author":"Roberts","year":"2025","journal-title":"Drug Target Rev."},{"key":"10.1016\/j.jmb.2025.169473_b1490","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/bit.27713","article-title":"Design of synthetic promoters for controlled expression of therapeutic genes in retinal pigment epithelial cells","volume":"118","author":"Johari","year":"2021","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jmb.2025.169473_b1495","doi-asserted-by":"crossref","first-page":"47","DOI":"10.32607\/actanaturae.11063","article-title":"Muscle-specific promoters for gene therapy","volume":"13","author":"Skopenkova","year":"2021","journal-title":"Acta Nature"},{"key":"10.1016\/j.jmb.2025.169473_b1500","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14712598.2011.562496","article-title":"Genotoxicity of retroviral hematopoietic stem cell gene therapy","volume":"11","author":"Trobridge","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0020060","article-title":"Retroviral DNA integration: viral and cellular determinants of target-site selection","volume":"2","author":"Lewinski","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jmb.2025.169473_b1510","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omtm.2018.11.001","article-title":"Shifting retroviral vector integrations away from transcriptional start sites via DNA-binding protein domain insertion into integrase","volume":"12","author":"Nam","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1515","doi-asserted-by":"crossref","first-page":"9524","DOI":"10.1128\/JVI.78.17.9524-9537.2004","article-title":"LEDGF\/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes","volume":"78","author":"Llano","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1520","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.3390\/v5102483","article-title":"Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes","volume":"5","author":"Matreyek","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b1525","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ebiom.2016.04.039","article-title":"LEDGIN-mediated inhibition of integrase\u2013LEDGF\/p75 interaction reduces reactivation of residual latent HIV","volume":"8","author":"Vranckx","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jmb.2025.169473_b1530","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/mt.2010.36","article-title":"LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin","volume":"18","author":"Gijsbers","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1535","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1128\/JVI.78.23.12735-12746.2004","article-title":"Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication","volume":"78","author":"Lu","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1540","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1128\/JVI.78.6.2906-2920.2004","article-title":"Unintegrated lentivirus DNA persistence and accessibility to expression in nondividing cells: analysis with class I integrase mutants","volume":"78","author":"Saenz","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1545","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/104303404322959515","article-title":"Novel integrase-defective lentiviral episomal vectors for gene transfer","volume":"15","author":"Vargas","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1550","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1128\/jvi.69.5.2729-2736.1995","article-title":"Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication","volume":"69","author":"Engelman","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1555","doi-asserted-by":"crossref","first-page":"10376","DOI":"10.1128\/JVI.77.19.10376-10382.2003","article-title":"Early transcription from nonintegrated DNA in human immunodeficiency virus infection","volume":"77","author":"Wu","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1560","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41586-018-0750-6","article-title":"NP220 mediates silencing of unintegrated retroviral DNA","volume":"564","author":"Zhu","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b1565","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-micro-091313-103409","article-title":"Cellular sensing of viral DNA and viral evasion mechanisms","volume":"68","author":"Orzalli","year":"2014","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.jmb.2025.169473_b1570","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1126\/science.1240933","article-title":"Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses","volume":"341","author":"Gao","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b1575","doi-asserted-by":"crossref","first-page":"E4571","DOI":"10.1073\/pnas.1311669110","article-title":"IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication","volume":"110","author":"Jakobsen","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b1580","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1742-4690-1-13","article-title":"HIV-1 gene expression: lessons from provirus and non-integrated DNA","volume":"1","author":"Wu","year":"2004","journal-title":"Retrovirology"},{"key":"10.1016\/j.jmb.2025.169473_b1585","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41564-018-0179-6","article-title":"HIV-2\/SIV viral protein X counteracts HUSH repressor complex","volume":"3","author":"Chougui","year":"2018","journal-title":"Nature Microbiol."},{"key":"10.1016\/j.jmb.2025.169473_b1590","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41564-018-0256-x","article-title":"Primate immunodeficiency virus proteins Vpx and Vpr counteract transcriptional repression of proviruses by the HUSH complex","volume":"3","author":"Yurkovetskiy","year":"2018","journal-title":"Nature Microbiol."},{"key":"10.1016\/j.jmb.2025.169473_b1595","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4014\/jmb.2309.09022","article-title":"A replication-competent retroviral vector expressing the HERV-W envelope glycoprotein is a potential tool for cancer gene therapy","volume":"34","author":"Kang","year":"2024","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1600","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-07-0151","article-title":"Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors","volume":"13","author":"Kikuchi","year":"2007","journal-title":"Clin. Cancer Res. off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jmb.2025.169473_b1605","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11060-010-0295-5","article-title":"Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma","volume":"102","author":"Hlavaty","year":"2011","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.jmb.2025.169473_b1610","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/cgt.2011.25","article-title":"Replication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesothelioma","volume":"18","author":"Kawasaki","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1615","first-page":"100","article-title":"Construction and properties of replication-competent murine retroviral vectors encoding methotrexate resistance","volume":"9","author":"Stuhlmann","year":"1989","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169473_b1620","first-page":"E25","article-title":"Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model","volume":"20","author":"Wang","year":"2006","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.jmb.2025.169473_b1625","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/104303403321070810","article-title":"Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors","volume":"14","author":"Wang","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1630","series-title":"Viral Vectors Vaccine Deliv.","first-page":"91","article-title":"Replication-Competent Viral Vectors for Vaccine Delivery","author":"Chavda","year":"2025"},{"key":"10.1016\/j.jmb.2025.169473_b1635","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1080\/14712598.2021.1902982","article-title":"Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer","volume":"21","author":"Collins","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1640","article-title":"Smoldering oncolysis by foamy virus carrying CD19 as a CAR target escapes CAR T detection by genomic modification","volume":"32","author":"Tonne","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.jmb.2025.169473_b1645","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3390\/biomedicines12102265","article-title":"Establishment and characterization of a stable producer cell line generation platform for the manufacturing of clinical-grade lentiviral vectors","volume":"12","author":"Arrasate","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.jmb.2025.169473_b1650","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1089\/hum.2009.165","article-title":"Integrated strategy for the production of therapeutic retroviral vectors","volume":"22","author":"Carrondo","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1655","article-title":"Continuous manufacturing of lentiviral vectors using a stable producer cell line in a fixed-bed bioreactor","volume":"32","author":"Stibbs","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1660","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddv451","article-title":"Progress and challenges in viral vector manufacturing","volume":"25","author":"van der Loo","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jmb.2025.169473_b1665","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1073\/pnas.81.20.6349","article-title":"High-efficiency gene transfer into mammalian cells: generation of helper-free recombinant retrovirus with broad mammalian host range","volume":"81","author":"Cone","year":"1984","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2025.169473_b1670","first-page":"2895","article-title":"Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production","volume":"6","author":"Miller","year":"1986","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2025.169473_b1675","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1128\/JVI.72.4.2671-2676.1998","article-title":"Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells","volume":"72","author":"Patience","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1680","doi-asserted-by":"crossref","first-page":"8001","DOI":"10.1128\/jvi.68.12.8001-8007.1994","article-title":"Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell","volume":"68","author":"Takeuchi","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1685","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/mthe.2000.0123","article-title":"Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer","volume":"2","author":"Sheridan","year":"2000","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1690","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.gt.3301457","article-title":"Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors","volume":"8","author":"Pizzato","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1695","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1089\/hum.1997.8.12-1459","article-title":"Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies","volume":"8","author":"Davis","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1700","doi-asserted-by":"crossref","DOI":"10.1002\/biot.202000017","article-title":"Progress and perspectives in the development of lentiviral vector producer cells","volume":"16","author":"Ferreira","year":"2021","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.jmb.2025.169473_b1705","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.964397","article-title":"The impact of serum-free culture on HEK293 cells: from the establishment of suspension and adherent serum-free adaptation cultures to the investigation of growth and metabolic profiles","volume":"10","author":"Jang","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1710","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1038\/s41598-018-23593-y","article-title":"LentiPro26: novel stable cell lines for constitutive lentiviral vector production","volume":"8","author":"Tom\u00e1s","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169473_b1715","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.13005\/bpj\/3198","article-title":"Development of serum-free medium and suspension culture for HEK293 cells using systematic optimization strategies","volume":"18","author":"Xu","year":"2025","journal-title":"Biomed. Pharmacol. J."},{"key":"10.1016\/j.jmb.2025.169473_b1720","doi-asserted-by":"crossref","unstructured":"A. Chatel, Key considerations for scalable retroviral vector production\u2014with a focus on lentivirus, 2025. https:\/\/www.insights.bio\/cell-and-gene-therapy-insights\/journal\/article\/3525\/key-considerations-for-scalable-retroviral-vector-productionwith-a-focus-on-lentivirus (accessed September 2, 2025).","DOI":"10.18609\/cgti.2025.068"},{"key":"10.1016\/j.jmb.2025.169473_b1725","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1128\/jvi.70.8.5701-5705.1996","article-title":"The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses","volume":"70","author":"Naviaux","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.jmb.2025.169473_b1730","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/v3060677","article-title":"Gammaretroviral Vectors: Biology, Technology and Application","volume":"3","author":"Maetzig","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.jmb.2025.169473_b1735","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.bej.2009.10.017","article-title":"Recent progress in lentiviral vector mass production","volume":"48","author":"Ansorge","year":"2010","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.jmb.2025.169473_b1740","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/bit.21467","article-title":"Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification","volume":"98","author":"Segura","year":"2007","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.jmb.2025.169473_b1745","doi-asserted-by":"crossref","first-page":"16017","DOI":"10.1038\/mtm.2016.17","article-title":"Production of lentiviral vectors","volume":"3","author":"Merten","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1750","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.mt.6300383","article-title":"Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture","volume":"16","author":"Broussau","year":"2008","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1755","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ymthe.2005.12.015","article-title":"A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors","volume":"14","author":"Cockrell","year":"2006","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1760","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2174\/156652310793797748","article-title":"Large-scale production means for the manufacturing of lentiviral vectors","volume":"10","author":"Schweizer","year":"2010","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1765","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/hum.2010.142","article-title":"A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson\u2019s disease","volume":"22","author":"Stewart","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1770","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1182\/blood-2008-11-191049","article-title":"Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection","volume":"113","author":"Throm","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jmb.2025.169473_b1775","doi-asserted-by":"crossref","first-page":"14063","DOI":"10.1038\/mtm.2014.63","article-title":"Generation of a lentiviral vector producer cell clone for human Wiskott-Aldrich syndrome gene therapy","volume":"2","author":"Wielgosz","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1780","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/mthe.2000.0238","article-title":"Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors","volume":"3","author":"Xu","year":"2001","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1785","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-2867-5-27","article-title":"Establishment of a doxycycline-regulated cell line with inducible, doubly-stable expression of the wild-type p53 gene from p53-deleted hepatocellular carcinoma cells","volume":"5","author":"Chi","year":"2005","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.jmb.2025.169473_b1790","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nbt815","article-title":"Continuous high-titer HIV-1 vector production","volume":"21","author":"Ikeda","year":"2003","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1795","doi-asserted-by":"crossref","first-page":"16033","DOI":"10.1038\/mtm.2016.33","article-title":"RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope","volume":"3","author":"Marin","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1800","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1038\/srep09021","article-title":"Construction of stable packaging cell lines for clinical lentiviral vector production","volume":"5","author":"Sanber","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169473_b1805","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/hgtb.2012.190","article-title":"RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy","volume":"24","author":"Stornaiuolo","year":"2013","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.jmb.2025.169473_b1810","doi-asserted-by":"crossref","DOI":"10.1016\/j.bej.2021.108202","article-title":"Gene therapy process change evaluation framework: transient transfection and stable producer cell line comparison","volume":"176","author":"Comisel","year":"2021","journal-title":"Biochem. Eng. J."},{"key":"10.1016\/j.jmb.2025.169473_b1815","article-title":"Optimizing transient transfection for viral vector production","author":"Alvaro","year":"2022","journal-title":"Pharma\u2019s Alm."},{"key":"10.1016\/j.jmb.2025.169473_b1820","article-title":"Stable vs transient expression: which to use and when?","author":"Eppendorf","year":"2024","journal-title":"Eppendorf Lab Acad."},{"key":"10.1016\/j.jmb.2025.169473_b1825","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b1830","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of a\u2022t to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b1835","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.jmb.2025.169473_b1840","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","article-title":"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III","volume":"471","author":"Deltcheva","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b1845","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b1850","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR-Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.jmb.2025.169473_b1855","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41592-020-01003-4","article-title":"Guide RNAs: it\u2019s good to be choosy","volume":"17","author":"Marx","year":"2020","journal-title":"Nature Methods"},{"key":"10.1016\/j.jmb.2025.169473_b1860","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1146\/annurev-chembioeng-080615-034711","article-title":"Engineering delivery vehicles for genome editing","volume":"7","author":"Nelson","year":"2016","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"10.1016\/j.jmb.2025.169473_b1865","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd.2016.280","article-title":"Delivery technologies for genome editing","volume":"16","author":"Yin","year":"2017","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.jmb.2025.169473_b1870","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 therapeutics: progress and prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1875","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jmb.2025.169473_b1880","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nature Methods"},{"key":"10.1016\/j.jmb.2025.169473_b1885","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Heckl","year":"2014","journal-title":"Nature Biotechnol."},{"key":"10.1016\/j.jmb.2025.169473_b1890","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2025.169473_b1895","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/gt.2016.27","article-title":"Lentivirus pre-packed with Cas9 protein for safer gene editing","volume":"23","author":"Choi","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1900","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1038\/s41467-020-18875-x","article-title":"In vivo CRISPR\/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells","volume":"11","author":"Martinez-Lage","year":"2020","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2025.169473_b1905","doi-asserted-by":"crossref","first-page":"25611","DOI":"10.1038\/srep25611","article-title":"A retroviral CRISPR-Cas9 system for cellular autism-associated phenotype discovery in developing neurons","volume":"6","author":"Williams","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2025.169473_b1910","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.omtm.2017.04.002","article-title":"Integrase-deficient lentiviral vector as an all-in-one platform for highly efficient CRISPR\/Cas9-mediated gene editing","volume":"5","author":"Ortinski","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1915","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.omtn.2018.09.006","article-title":"Transient retrovirus-based CRISPR\/Cas9 all-in-one particles for efficient, targeted gene knockout","volume":"13","author":"Knopp","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.jmb.2025.169473_b1920","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/hum.2015.074","article-title":"Delivery and specificity of CRISPR-Cas9 genome editing technologies for human gene therapy","volume":"26","author":"Gori","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1925","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2025.169473_b1930","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2021.02.022","article-title":"Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease","volume":"21","author":"Uchida","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1935","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/life10120366","article-title":"Virus-like particle Mediated CRISPR\/Cas9 delivery for efficient and safe genome editing","volume":"10","author":"Lyu","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.jmb.2025.169473_b1940","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.omtn.2021.12.033","article-title":"Improved alpharetrovirus-based Gag.MS2 particles for efficient and transient delivery of CRISPR-Cas9 into target cells","volume":"27","author":"Baron","year":"2022","journal-title":"Mol. Ther. \u2013 Nucleic Acids"},{"key":"10.1016\/j.jmb.2025.169473_b1945","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/nar\/gkz093","article-title":"Delivering SaCas9 mRNA by lentivirus-like bionanoparticles for transient expression and efficient genome editing","volume":"47","author":"Lu","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2025.169473_b1950","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12915-021-01214-x","article-title":"CRISPR\/Cas9-mediated gene knockout and interallelic gene conversion in human induced pluripotent stem cells using non-integrative bacteriophage-chimeric retrovirus-like particles","volume":"20","author":"Miann\u00e9","year":"2022","journal-title":"BMC Biol."},{"key":"10.1016\/j.jmb.2025.169473_b1955","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.omtm.2022.11.009","article-title":"Meeting FDA guidance recommendations for replication-competent virus and insertional oncogenesis testing","volume":"28","author":"Cornetta","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jmb.2025.169473_b1960","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2022.12.006","article-title":"Replication competent retrovirus testing (RCR) in the national gene vector biorepository: no evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials","volume":"31","author":"Cornetta","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jmb.2025.169473_b1965","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","article-title":"Retroviral Insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones","volume":"28","author":"Bushman","year":"2020","journal-title":"Mol. Ther."}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002228362500539X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002228362500539X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:59:13Z","timestamp":1781006353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002228362500539X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":393,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S002228362500539X"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2025.169473","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2025.169473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"169473"}}